e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Late-Breaking Abstracts Session: New treatments and targets for airway disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late-breaking abstract: Pre-clinical efficacy of RP5090 in PI3Kδ mediated airway disorders
K. Routhu, K. Varanasi, S. Veeraraghavan, M. Muthuppalaniappan, G. Babu, S. Viswanadha, S. Vakkalanka (Hyderabad, India)
Source:
Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease
Session:
Late-Breaking Abstracts Session: New treatments and targets for airway disease
Session type:
Oral Presentation
Number:
4495
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Routhu, K. Varanasi, S. Veeraraghavan, M. Muthuppalaniappan, G. Babu, S. Viswanadha, S. Vakkalanka (Hyderabad, India). Late-breaking abstract: Pre-clinical efficacy of RP5090 in PI3Kδ mediated airway disorders. Eur Respir J 2011; 38: Suppl. 55, 4495
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Late-breaking abstract: Further studies on the mechanism of action of doxofylline
Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New mechanisms in airway disease
Year: 2011
Late-breaking abstract: Preclinical evaluation of an inhibitor of cytosolic phospholipase A
2
α for the treatment of asthma
Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease
Year: 2011
Late-breaking abstract: Genome-wide association of
GLCCI1
with asthma steroid treatment response
Source: Annual Congress 2011 - Phenotyping asthma: a clue for treatments?
Year: 2011
Late-breaking abstract: Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders
Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease
Year: 2011
Safety of formoterol in asthma clinical trials: an update
Source: Eur Respir J 2014; 43: 103-114
Year: 2004
Paradoxical response to bronchodilators: Radiologic correlates and clinical implications
Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases
Year: 2014
Late-breaking abstract: HR-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease
Source: Annual Congress 2011 - COPD: integrated care and rehabilitation
Year: 2011
Initial trials of precision medicine approaches in airway disease
Source: ERS Research Seminar 2017 – Precision medicine in airway diseases
Year: 2017
Pulmonary fibrosis: ongoing trials and future treatment
Source: Research Seminar 2010 - Novel insights in pulmonary fibrogenesis: from bench to bedside Research Seminar
Year: 2010
Bronchodilator response and airway cytology as parameters for asthma control: A randomized clinical trial Protocol ID: APITA, NCT00597064, on August 1
st
, 2008
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012
Challenges in IPF trials: the point on endpoints
Source: Annual Congress 2010 - Idiopathic pulmonary fibrosis: present understandings and future directions
Year: 2010
Tiotropium in severe asthma: an open label review of clinical efficacy
Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Year: 2007
Precision medicine in airway diseases: moving to clinical practice
Source: Eur Respir J, 50 (4) 1701655; 10.1183/13993003.01655-2017
Year: 2017
Clinical efficacy of new non-freon aerosol troventol in asthma patients
Source: Annual Congress 2006 - Recent advances in asthma treatment
Year: 2006
Safety of formoterol in children and adolescents: experience from asthma clinical trials
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008
Genetic studies in asthma and COPD: what have we learned?
Source: Annual Congress 2011 - PG5 Asthma versus COPD: similarities and differences
Year: 2011
Measuring airway hyperresponsiveness: does it add to routine measures of clinical efficacy in guiding asthma therapy?
Source: Eur Respir J 2006; 28: Suppl. 50, 319s
Year: 2006
Late-breaking abstract: Nasal symptoms are common in subjects with COPD and concomitant heart disease
Source: Annual Congress 2011 - COPD: burden of disease, imaging and management
Year: 2011
Clinical trials are important for CAP and other LRTI syndromes: but how to understand and interpret?
Source: Annual Congress 2010 - PG17 GRACE Postgraduate Course: Antimicrobial treatment of LRTI: important new aspects for clinical practice
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept